JP2017513879A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017513879A5 JP2017513879A5 JP2016563976A JP2016563976A JP2017513879A5 JP 2017513879 A5 JP2017513879 A5 JP 2017513879A5 JP 2016563976 A JP2016563976 A JP 2016563976A JP 2016563976 A JP2016563976 A JP 2016563976A JP 2017513879 A5 JP2017513879 A5 JP 2017513879A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- dihydro
- oxo
- alkyl
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 97
- 150000003839 salts Chemical class 0.000 claims 96
- 150000001875 compounds Chemical class 0.000 claims 86
- 125000001424 substituent group Chemical group 0.000 claims 35
- 125000003118 aryl group Chemical group 0.000 claims 29
- 229910052799 carbon Inorganic materials 0.000 claims 29
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 26
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 25
- 125000005843 halogen group Chemical group 0.000 claims 25
- 229910052739 hydrogen Inorganic materials 0.000 claims 21
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 21
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 19
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 16
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 16
- 125000004432 carbon atom Chemical group C* 0.000 claims 16
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 15
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 14
- -1 pyran-4-yl Chemical group 0.000 claims 14
- 239000003814 drug Substances 0.000 claims 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims 9
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 8
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 8
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 7
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 6
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 claims 6
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 4
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 4
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 230000002062 proliferating effect Effects 0.000 claims 4
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 229940127557 pharmaceutical product Drugs 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- YMXDUJHQMMRCDQ-UHFFFAOYSA-N 2-[6-methoxy-8-(6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridin-4-yl)-3-oxo-2-propan-2-yl-1,4-benzoxazin-4-yl]acetic acid Chemical compound C(C)(C)C1OC2=C(N(C1=O)CC(=O)O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)OC YMXDUJHQMMRCDQ-UHFFFAOYSA-N 0.000 claims 1
- CUTSJIQRJNXWGF-UHFFFAOYSA-N 8-(6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridin-4-yl)-2-propan-2-yl-6-propan-2-ylsulfonyl-4H-1,4-benzoxazin-3-one Chemical compound C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)C(C)C CUTSJIQRJNXWGF-UHFFFAOYSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- BHRFIRJQNJWMER-UHFFFAOYSA-N C(C)(=O)C=1C=C(C2=C(N(C(C(O2)(C)C)=O)C)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 Chemical compound C(C)(=O)C=1C=C(C2=C(N(C(C(O2)(C)C)=O)C)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 BHRFIRJQNJWMER-UHFFFAOYSA-N 0.000 claims 1
- GBDDCVVMMBUQSS-UHFFFAOYSA-N C(C)(=O)C=1C=C(C2=C(NC(C(O2)(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 Chemical compound C(C)(=O)C=1C=C(C2=C(NC(C(O2)(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 GBDDCVVMMBUQSS-UHFFFAOYSA-N 0.000 claims 1
- KMEAPQYZZXHZGP-UHFFFAOYSA-N C(C)(=O)C=1C=C(C2=C(NC(C(O2)C(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 Chemical compound C(C)(=O)C=1C=C(C2=C(NC(C(O2)C(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 KMEAPQYZZXHZGP-UHFFFAOYSA-N 0.000 claims 1
- RKMKZCHLXSZZSO-UHFFFAOYSA-N C(C)(C)C1OC2=C(N(C1)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)OC Chemical compound C(C)(C)C1OC2=C(N(C1)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)OC RKMKZCHLXSZZSO-UHFFFAOYSA-N 0.000 claims 1
- BZDMBDBFOSIAJM-UHFFFAOYSA-N C(C)(C)C1OC2=C(N(C1=O)C(C)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)OC Chemical compound C(C)(C)C1OC2=C(N(C1=O)C(C)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)OC BZDMBDBFOSIAJM-UHFFFAOYSA-N 0.000 claims 1
- MWRTXNSJFNRWGB-UHFFFAOYSA-N C(C)(C)C1OC2=C(N(C1=O)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)C#N Chemical compound C(C)(C)C1OC2=C(N(C1=O)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)C#N MWRTXNSJFNRWGB-UHFFFAOYSA-N 0.000 claims 1
- VCVIXEIJKSXPNT-UHFFFAOYSA-N C(C)(C)C1OC2=C(N(C1=O)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)C(=O)N Chemical compound C(C)(C)C1OC2=C(N(C1=O)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)C(=O)N VCVIXEIJKSXPNT-UHFFFAOYSA-N 0.000 claims 1
- SXYZTRGYEAVJIW-UHFFFAOYSA-N C(C)(C)C1OC2=C(N(C1=O)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)OC Chemical compound C(C)(C)C1OC2=C(N(C1=O)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)OC SXYZTRGYEAVJIW-UHFFFAOYSA-N 0.000 claims 1
- WGOXPRDASYHAQQ-UHFFFAOYSA-N C(C)(C)C1OC2=C(N(C1=O)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)C Chemical compound C(C)(C)C1OC2=C(N(C1=O)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)C WGOXPRDASYHAQQ-UHFFFAOYSA-N 0.000 claims 1
- ACIXQIIPFSJIFH-UHFFFAOYSA-N C(C)(C)C1OC2=C(N(C1=O)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)C(C)C Chemical compound C(C)(C)C1OC2=C(N(C1=O)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)C(C)C ACIXQIIPFSJIFH-UHFFFAOYSA-N 0.000 claims 1
- WFWRYNWEIWQCDH-UHFFFAOYSA-N C(C)(C)C1OC2=C(N(C1=O)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)N(C)C Chemical compound C(C)(C)C1OC2=C(N(C1=O)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)N(C)C WFWRYNWEIWQCDH-UHFFFAOYSA-N 0.000 claims 1
- RSTKTMLTNCOEFQ-UHFFFAOYSA-N C(C)(C)C1OC2=C(N(C1=O)CC(=O)N)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)OC Chemical compound C(C)(C)C1OC2=C(N(C1=O)CC(=O)N)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)OC RSTKTMLTNCOEFQ-UHFFFAOYSA-N 0.000 claims 1
- DTJGBPPBPZKKBJ-UHFFFAOYSA-N C(C)(C)C1OC2=C(N(C1=O)CC(=O)N1CCN(CC1)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)OC Chemical compound C(C)(C)C1OC2=C(N(C1=O)CC(=O)N1CCN(CC1)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)OC DTJGBPPBPZKKBJ-UHFFFAOYSA-N 0.000 claims 1
- JAVNUIONZCKOSO-UHFFFAOYSA-N C(C)(C)C1OC2=C(N(C1=O)CC(=O)NC)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)OC Chemical compound C(C)(C)C1OC2=C(N(C1=O)CC(=O)NC)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)OC JAVNUIONZCKOSO-UHFFFAOYSA-N 0.000 claims 1
- XMCVATSPPKKRPO-UHFFFAOYSA-N C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)C#N Chemical compound C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)C#N XMCVATSPPKKRPO-UHFFFAOYSA-N 0.000 claims 1
- VJPORROVNJWNTH-UHFFFAOYSA-N C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)C(=O)N Chemical compound C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)C(=O)N VJPORROVNJWNTH-UHFFFAOYSA-N 0.000 claims 1
- XLCCRKYGUWVTNE-UHFFFAOYSA-N C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)C(=O)N(C)C Chemical compound C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)C(=O)N(C)C XLCCRKYGUWVTNE-UHFFFAOYSA-N 0.000 claims 1
- PZEAIFBAKMIROG-UHFFFAOYSA-N C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)C(=O)N1CCOCC1 Chemical compound C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)C(=O)N1CCOCC1 PZEAIFBAKMIROG-UHFFFAOYSA-N 0.000 claims 1
- HABYNDWUMBDLSU-UHFFFAOYSA-N C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)C(=O)NC Chemical compound C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)C(=O)NC HABYNDWUMBDLSU-UHFFFAOYSA-N 0.000 claims 1
- WEBIPQYYGQULER-UHFFFAOYSA-N C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)C=1C=NN(C1)C Chemical compound C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)C=1C=NN(C1)C WEBIPQYYGQULER-UHFFFAOYSA-N 0.000 claims 1
- ZOIAALYHIWXWIE-UHFFFAOYSA-N C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)CNC(C)=O Chemical compound C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)CNC(C)=O ZOIAALYHIWXWIE-UHFFFAOYSA-N 0.000 claims 1
- WSYTXPXMORQZPT-UHFFFAOYSA-N C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)CNS(=O)(=O)CC Chemical compound C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)CNS(=O)(=O)CC WSYTXPXMORQZPT-UHFFFAOYSA-N 0.000 claims 1
- KTPJSJZLDJHYMM-UHFFFAOYSA-N C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)COC Chemical compound C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)COC KTPJSJZLDJHYMM-UHFFFAOYSA-N 0.000 claims 1
- KRJWGRKYQVYBNX-UHFFFAOYSA-N C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)OC Chemical compound C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)OC KRJWGRKYQVYBNX-UHFFFAOYSA-N 0.000 claims 1
- MQXCZCZVDCBXEP-UHFFFAOYSA-N C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)C Chemical compound C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)C MQXCZCZVDCBXEP-UHFFFAOYSA-N 0.000 claims 1
- NEPDDSPFRJKQIG-UHFFFAOYSA-N C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)N(C)C Chemical compound C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)N(C)C NEPDDSPFRJKQIG-UHFFFAOYSA-N 0.000 claims 1
- RQCFRYCIVSTQQX-UHFFFAOYSA-N C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)NC Chemical compound C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)NC RQCFRYCIVSTQQX-UHFFFAOYSA-N 0.000 claims 1
- BJFXRUBKKJTYMK-UHFFFAOYSA-N C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)[N+](=O)[O-] Chemical compound C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)[N+](=O)[O-] BJFXRUBKKJTYMK-UHFFFAOYSA-N 0.000 claims 1
- BHCQUZIQSDHQBI-UHFFFAOYSA-N C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NN=C1)OC Chemical compound C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NN=C1)OC BHCQUZIQSDHQBI-UHFFFAOYSA-N 0.000 claims 1
- YMPUSWXZNSDLQT-UHFFFAOYSA-N C(C)(C)C1OC2=C(NC1=O)C=CC=C2C=2C1=C(C(N(C2)C)=O)NC=C1 Chemical compound C(C)(C)C1OC2=C(NC1=O)C=CC=C2C=2C1=C(C(N(C2)C)=O)NC=C1 YMPUSWXZNSDLQT-UHFFFAOYSA-N 0.000 claims 1
- FACZPYRLHYCURA-UHFFFAOYSA-N C(C)(C)NS(=O)(=O)C=1C=C(C2=C(NC(C(O2)(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 Chemical compound C(C)(C)NS(=O)(=O)C=1C=C(C2=C(NC(C(O2)(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 FACZPYRLHYCURA-UHFFFAOYSA-N 0.000 claims 1
- HNQLCPAQQAHVOG-UHFFFAOYSA-N C(C)(C)S(=O)(=O)C=1C=C(C2=C(N(C(C(O2)(C)C)=O)C)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 Chemical compound C(C)(C)S(=O)(=O)C=1C=C(C2=C(N(C(C(O2)(C)C)=O)C)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 HNQLCPAQQAHVOG-UHFFFAOYSA-N 0.000 claims 1
- IFMPPLILXDJTER-UHFFFAOYSA-N C(C)(C)S(=O)(=O)C=1C=C(C2=C(NC(C(O2)(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 Chemical compound C(C)(C)S(=O)(=O)C=1C=C(C2=C(NC(C(O2)(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 IFMPPLILXDJTER-UHFFFAOYSA-N 0.000 claims 1
- SSYAJZNGKRVZDT-MRXNPFEDSA-N C(C)(C)[C@@H]1C(NC2=CC(=CC(=C2N1)C=1C2=C(C(N(C1)C)=O)NC=C2)S(=O)(=O)C)=O Chemical compound C(C)(C)[C@@H]1C(NC2=CC(=CC(=C2N1)C=1C2=C(C(N(C1)C)=O)NC=C2)S(=O)(=O)C)=O SSYAJZNGKRVZDT-MRXNPFEDSA-N 0.000 claims 1
- SSYAJZNGKRVZDT-INIZCTEOSA-N C(C)(C)[C@H]1C(NC2=CC(=CC(=C2N1)C=1C2=C(C(N(C1)C)=O)NC=C2)S(=O)(=O)C)=O Chemical compound C(C)(C)[C@H]1C(NC2=CC(=CC(=C2N1)C=1C2=C(C(N(C1)C)=O)NC=C2)S(=O)(=O)C)=O SSYAJZNGKRVZDT-INIZCTEOSA-N 0.000 claims 1
- FCOINXWHXDCOAG-UHFFFAOYSA-N C(C)C1OC2=C(N(C1=O)C)C=CC=C2C=2C1=C(C(N(C2)C)=O)NC=C1 Chemical compound C(C)C1OC2=C(N(C1=O)C)C=CC=C2C=2C1=C(C(N(C2)C)=O)NC=C1 FCOINXWHXDCOAG-UHFFFAOYSA-N 0.000 claims 1
- QNVIRBIENGAFTI-UHFFFAOYSA-N C(C)C1OC2=C(NC1=O)C=CC=C2C=2C1=C(C(N(C2)C)=O)NC=C1 Chemical compound C(C)C1OC2=C(NC1=O)C=CC=C2C=2C1=C(C(N(C2)C)=O)NC=C1 QNVIRBIENGAFTI-UHFFFAOYSA-N 0.000 claims 1
- NJXCTPVBHMBLOD-UHFFFAOYSA-N C(C)N1C(C(OC2=C1C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)C)C(C)C)=O Chemical compound C(C)N1C(C(OC2=C1C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)C)C(C)C)=O NJXCTPVBHMBLOD-UHFFFAOYSA-N 0.000 claims 1
- SAFVBAUCLGDZHX-UHFFFAOYSA-N C(C)S(=O)(=O)C=1C=C(C2=C(N(C(C(O2)(C)C)=O)C)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 Chemical compound C(C)S(=O)(=O)C=1C=C(C2=C(N(C(C(O2)(C)C)=O)C)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 SAFVBAUCLGDZHX-UHFFFAOYSA-N 0.000 claims 1
- AOFYESONCWVXOM-UHFFFAOYSA-N C(C)S(=O)(=O)C=1C=C(C2=C(N(C(C(O2)C(C)C)=O)C)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 Chemical compound C(C)S(=O)(=O)C=1C=C(C2=C(N(C(C(O2)C(C)C)=O)C)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 AOFYESONCWVXOM-UHFFFAOYSA-N 0.000 claims 1
- FXNXKAYEZZOSLM-UHFFFAOYSA-N C(C)S(=O)(=O)C=1C=C(C2=C(NC(C(O2)C(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 Chemical compound C(C)S(=O)(=O)C=1C=C(C2=C(NC(C(O2)C(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 FXNXKAYEZZOSLM-UHFFFAOYSA-N 0.000 claims 1
- YFEHNICKIWSDPK-UHFFFAOYSA-N C1(CC1)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)OC Chemical compound C1(CC1)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)OC YFEHNICKIWSDPK-UHFFFAOYSA-N 0.000 claims 1
- FYVGXSSFEOIVOH-UHFFFAOYSA-N C1(CC1)CN1C(C(OC2=C1C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)C)C(C)C)=O Chemical compound C1(CC1)CN1C(C(OC2=C1C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)C)C(C)C)=O FYVGXSSFEOIVOH-UHFFFAOYSA-N 0.000 claims 1
- APVTWFGLNNDNFT-UHFFFAOYSA-N C1(CCCC1)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)OC Chemical compound C1(CCCC1)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)OC APVTWFGLNNDNFT-UHFFFAOYSA-N 0.000 claims 1
- ZQNWOJLLSNTBOT-UHFFFAOYSA-N C1(CCCC1)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NN=C1)OC Chemical compound C1(CCCC1)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NN=C1)OC ZQNWOJLLSNTBOT-UHFFFAOYSA-N 0.000 claims 1
- GEOFFFTZVWEORK-UHFFFAOYSA-N CC1(C(NC2=CC(=CC(=C2N1)C=1C2=C(C(N(C1)C)=O)NC=C2)S(=O)(=O)C)=O)C Chemical compound CC1(C(NC2=CC(=CC(=C2N1)C=1C2=C(C(N(C1)C)=O)NC=C2)S(=O)(=O)C)=O)C GEOFFFTZVWEORK-UHFFFAOYSA-N 0.000 claims 1
- ITBPPWDYISFPIQ-UHFFFAOYSA-N CC1(C(NC2=CC=CC(=C2N1)C=1C2=C(C(N(C1)C)=O)NC=C2)=O)C Chemical compound CC1(C(NC2=CC=CC(=C2N1)C=1C2=C(C(N(C1)C)=O)NC=C2)=O)C ITBPPWDYISFPIQ-UHFFFAOYSA-N 0.000 claims 1
- VZSAMEOETVNDQH-UHFFFAOYSA-N CC1(OC2=C(N(C1=O)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)C)C Chemical compound CC1(OC2=C(N(C1=O)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)C)C VZSAMEOETVNDQH-UHFFFAOYSA-N 0.000 claims 1
- AOCBNYMNFJBMMG-UHFFFAOYSA-N CC1(OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)C)C Chemical compound CC1(OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)C)C AOCBNYMNFJBMMG-UHFFFAOYSA-N 0.000 claims 1
- WQVKFRLTBDFPLL-UHFFFAOYSA-N CC1(OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)N1CCCCC1)C Chemical compound CC1(OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)N1CCCCC1)C WQVKFRLTBDFPLL-UHFFFAOYSA-N 0.000 claims 1
- UGCRLJZYPLBALO-UHFFFAOYSA-N CC1(OC2=C(NC1=O)C=CC=C2C=2C1=C(C(N(C2)C)=O)NC=C1)C Chemical compound CC1(OC2=C(NC1=O)C=CC=C2C=2C1=C(C(N(C2)C)=O)NC=C1)C UGCRLJZYPLBALO-UHFFFAOYSA-N 0.000 claims 1
- JPPMQCVPYJFEDM-UHFFFAOYSA-N CC1OC2=C(NC1=O)C=CC=C2C=2C1=C(C(N(C2)C)=O)NC=C1 Chemical compound CC1OC2=C(NC1=O)C=CC=C2C=2C1=C(C(N(C2)C)=O)NC=C1 JPPMQCVPYJFEDM-UHFFFAOYSA-N 0.000 claims 1
- HBMRYZMTMNSJHQ-UHFFFAOYSA-N CN(S(=O)(=O)C=1C=C(C2=C(N(C(C(O2)(C)C)=O)C)C1)C=1C2=C(C(N(C1)C)=O)NC=C2)C Chemical compound CN(S(=O)(=O)C=1C=C(C2=C(N(C(C(O2)(C)C)=O)C)C1)C=1C2=C(C(N(C1)C)=O)NC=C2)C HBMRYZMTMNSJHQ-UHFFFAOYSA-N 0.000 claims 1
- XDULBZUBUWDUQX-UHFFFAOYSA-N CN(S(=O)(=O)C=1C=C(C2=C(NC(C(O2)(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2)C Chemical compound CN(S(=O)(=O)C=1C=C(C2=C(NC(C(O2)(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2)C XDULBZUBUWDUQX-UHFFFAOYSA-N 0.000 claims 1
- HNVGNTKAVBOFFJ-UHFFFAOYSA-N CN1C(C2(OC3=C1C=C(C=C3C=3C1=C(C(N(C3)C)=O)NC=C1)S(=O)(=O)C)CC2)=O Chemical compound CN1C(C2(OC3=C1C=C(C=C3C=3C1=C(C(N(C3)C)=O)NC=C1)S(=O)(=O)C)CC2)=O HNVGNTKAVBOFFJ-UHFFFAOYSA-N 0.000 claims 1
- DCRSESOZHPEKDC-UHFFFAOYSA-N CN1C(C2(OC3=C1C=C(C=C3C=3C1=C(C(N(C3)C)=O)NN=C1)S(=O)(=O)C)CC2)=O Chemical compound CN1C(C2(OC3=C1C=C(C=C3C=3C1=C(C(N(C3)C)=O)NN=C1)S(=O)(=O)C)CC2)=O DCRSESOZHPEKDC-UHFFFAOYSA-N 0.000 claims 1
- OTAWOJQJKMLEIJ-UHFFFAOYSA-N CN1C(C2=C(C(=C1)C1=CC(=CC=3NC(C(OC31)C3=CC=CC=C3)=O)S(=O)(=O)C)C=CN2)=O Chemical compound CN1C(C2=C(C(=C1)C1=CC(=CC=3NC(C(OC31)C3=CC=CC=C3)=O)S(=O)(=O)C)C=CN2)=O OTAWOJQJKMLEIJ-UHFFFAOYSA-N 0.000 claims 1
- PSNFDUYWYRHDGG-UHFFFAOYSA-N CN1C(C2=C(C(=C1)C1=CC(=CC=3NC(C4(OC31)CC4)=O)S(=O)(=O)C)C=CN2)=O Chemical compound CN1C(C2=C(C(=C1)C1=CC(=CC=3NC(C4(OC31)CC4)=O)S(=O)(=O)C)C=CN2)=O PSNFDUYWYRHDGG-UHFFFAOYSA-N 0.000 claims 1
- BJNFZKYTEAIKRD-UHFFFAOYSA-N CN1C(C2=C(C(=C1)C1=CC(=CC=3NC(C4(OC31)CC4)=O)S(=O)(=O)C)C=NN2)=O Chemical compound CN1C(C2=C(C(=C1)C1=CC(=CC=3NC(C4(OC31)CC4)=O)S(=O)(=O)C)C=NN2)=O BJNFZKYTEAIKRD-UHFFFAOYSA-N 0.000 claims 1
- DWZVOOLKEMMANA-UHFFFAOYSA-N CN1C(C2=C(C(=C1)C1=CC=CC=3NC(C(OC31)C3=CC=CC=C3)=O)C=CN2)=O Chemical compound CN1C(C2=C(C(=C1)C1=CC=CC=3NC(C(OC31)C3=CC=CC=C3)=O)C=CN2)=O DWZVOOLKEMMANA-UHFFFAOYSA-N 0.000 claims 1
- BHNIBBIFICVZCH-UHFFFAOYSA-N CN1C(C2=C(C(=C1)C1=CC=CC=3NC(C(OC31)C3CCOCC3)=O)C=CN2)=O Chemical compound CN1C(C2=C(C(=C1)C1=CC=CC=3NC(C(OC31)C3CCOCC3)=O)C=CN2)=O BHNIBBIFICVZCH-UHFFFAOYSA-N 0.000 claims 1
- WYJVNKCWTPZLLE-UHFFFAOYSA-N CN1C(C2=C(C(=C1)C1=CC=CC=3NC(C4(OC31)CC4)=O)C=CN2)=O Chemical compound CN1C(C2=C(C(=C1)C1=CC=CC=3NC(C4(OC31)CC4)=O)C=CN2)=O WYJVNKCWTPZLLE-UHFFFAOYSA-N 0.000 claims 1
- SZLGPPBPAXZKQQ-UHFFFAOYSA-N CN1C(C2=C(C(=C1)C=1C=C(C=C3NC(C4(CCC4)NC13)=O)S(=O)(=O)C)C=CN2)=O Chemical compound CN1C(C2=C(C(=C1)C=1C=C(C=C3NC(C4(CCC4)NC13)=O)S(=O)(=O)C)C=CN2)=O SZLGPPBPAXZKQQ-UHFFFAOYSA-N 0.000 claims 1
- JSNIIGHYZBWOSP-UHFFFAOYSA-N CN1C(C2=C(C(=C1)C=1C=C(C=C3NC(C4(CCCC4)NC13)=O)S(=O)(=O)C)C=CN2)=O Chemical compound CN1C(C2=C(C(=C1)C=1C=C(C=C3NC(C4(CCCC4)NC13)=O)S(=O)(=O)C)C=CN2)=O JSNIIGHYZBWOSP-UHFFFAOYSA-N 0.000 claims 1
- OIDVRFDJFDTSDS-UHFFFAOYSA-N CN1C(C2=C(C(=C1)C=1C=C(C=C3NC(C4(CCCCC4)NC13)=O)S(=O)(=O)C)C=CN2)=O Chemical compound CN1C(C2=C(C(=C1)C=1C=C(C=C3NC(C4(CCCCC4)NC13)=O)S(=O)(=O)C)C=CN2)=O OIDVRFDJFDTSDS-UHFFFAOYSA-N 0.000 claims 1
- WUOBHXKRFOEWOR-UHFFFAOYSA-N COC=1C=C(C2=C(NC(C(O2)(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NN=C2 Chemical compound COC=1C=C(C2=C(NC(C(O2)(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NN=C2 WUOBHXKRFOEWOR-UHFFFAOYSA-N 0.000 claims 1
- ZEABVHUCUWANHU-UHFFFAOYSA-N COC=1C=C(C2=C(NC(C(O2)C2=CC=CC=C2)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 Chemical compound COC=1C=C(C2=C(NC(C(O2)C2=CC=CC=C2)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 ZEABVHUCUWANHU-UHFFFAOYSA-N 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010008583 Chloroma Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- NNJNYMIRXGUCJK-UHFFFAOYSA-N ClC1=C(C=CC(=C1)F)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)OC Chemical compound ClC1=C(C=CC(=C1)F)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)OC NNJNYMIRXGUCJK-UHFFFAOYSA-N 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- SLFXKAJDMQVESP-UHFFFAOYSA-N FC(C(=O)O)(F)F.CN1C(C2=C(C(=C1)C1=CC=CC=3NC(C(OC31)C3=NC=CC=C3)=O)C=CN2)=O Chemical compound FC(C(=O)O)(F)F.CN1C(C2=C(C(=C1)C1=CC=CC=3NC(C(OC31)C3=NC=CC=C3)=O)C=CN2)=O SLFXKAJDMQVESP-UHFFFAOYSA-N 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 claims 1
- 241000701806 Human papillomavirus Species 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010023825 Laryngeal cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- BKQWIHVVMWEYDH-UHFFFAOYSA-N NCC=1C=C(C2=C(NC(C(O2)C(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 Chemical compound NCC=1C=C(C2=C(NC(C(O2)C(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 BKQWIHVVMWEYDH-UHFFFAOYSA-N 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- OKZRWDHEALFURO-UHFFFAOYSA-N O1C(=CC=C1)C=1C=C(C2=C(NC(C(O2)C(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 Chemical compound O1C(=CC=C1)C=1C=C(C2=C(NC(C(O2)C(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 OKZRWDHEALFURO-UHFFFAOYSA-N 0.000 claims 1
- AUHMZDOEKXETAW-UHFFFAOYSA-N OC(C)C=1C=C(C2=C(N(C(C(O2)(C)C)=O)C)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 Chemical compound OC(C)C=1C=C(C2=C(N(C(C(O2)(C)C)=O)C)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 AUHMZDOEKXETAW-UHFFFAOYSA-N 0.000 claims 1
- DXINHNGNHIKJDL-UHFFFAOYSA-N OC(C)C=1C=C(C2=C(NC(C(O2)(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 Chemical compound OC(C)C=1C=C(C2=C(NC(C(O2)(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 DXINHNGNHIKJDL-UHFFFAOYSA-N 0.000 claims 1
- NILVYPJGBOOINW-UHFFFAOYSA-N OC(C)C=1C=C(C2=C(NC(C(O2)C(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 Chemical compound OC(C)C=1C=C(C2=C(NC(C(O2)C(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 NILVYPJGBOOINW-UHFFFAOYSA-N 0.000 claims 1
- YNXBIVULWPMDOG-UHFFFAOYSA-N OCC=1C=C(C2=C(NC(C(O2)C(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 Chemical compound OCC=1C=C(C2=C(NC(C(O2)C(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 YNXBIVULWPMDOG-UHFFFAOYSA-N 0.000 claims 1
- AWKUZPDMHVLKQW-UHFFFAOYSA-N OCCC1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)C Chemical compound OCCC1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)C AWKUZPDMHVLKQW-UHFFFAOYSA-N 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims 1
- 206010034811 Pharyngeal cancer Diseases 0.000 claims 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000000389 T-cell leukemia Diseases 0.000 claims 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 206010043515 Throat cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000008385 Urogenital Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 claims 1
- 208000024519 eye neoplasm Diseases 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 201000005987 myeloid sarcoma Diseases 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000008106 ocular cancer Diseases 0.000 claims 1
- 208000027500 optic nerve neoplasm Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000010916 pituitary tumor Diseases 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000002314 small intestine cancer Diseases 0.000 claims 1
- 206010062261 spinal cord neoplasm Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 208000037964 urogenital cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 206010046885 vaginal cancer Diseases 0.000 claims 1
- 208000013139 vaginal neoplasm Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461983289P | 2014-04-23 | 2014-04-23 | |
| US61/983,289 | 2014-04-23 | ||
| PCT/US2015/027047 WO2015164480A1 (en) | 2014-04-23 | 2015-04-22 | 1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019147776A Division JP6745390B2 (ja) | 2014-04-23 | 2019-08-09 | ＢＥＴタンパク質阻害剤としての１Ｈ−ピロロ［２，３−ｃ］ピリジン−７（６Ｈ）−オン及びピラゾロ［３，４−ｃ］ピリジン−７（６Ｈ）−オン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017513879A JP2017513879A (ja) | 2017-06-01 |
| JP2017513879A5 true JP2017513879A5 (enExample) | 2018-06-07 |
| JP6572237B2 JP6572237B2 (ja) | 2019-09-04 |
Family
ID=53055117
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016563976A Active JP6572237B2 (ja) | 2014-04-23 | 2015-04-22 | ＢＥＴタンパク質阻害剤としての１Ｈ−ピロロ［２，３−ｃ］ピリジン−７（６Ｈ）−オン及びピラゾロ［３，４−ｃ］ピリジン−７（６Ｈ）−オン |
| JP2019147776A Active JP6745390B2 (ja) | 2014-04-23 | 2019-08-09 | ＢＥＴタンパク質阻害剤としての１Ｈ−ピロロ［２，３−ｃ］ピリジン−７（６Ｈ）−オン及びピラゾロ［３，４−ｃ］ピリジン−７（６Ｈ）−オン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019147776A Active JP6745390B2 (ja) | 2014-04-23 | 2019-08-09 | ＢＥＴタンパク質阻害剤としての１Ｈ−ピロロ［２，３−ｃ］ピリジン−７（６Ｈ）−オン及びピラゾロ［３，４−ｃ］ピリジン−７（６Ｈ）−オン |
Country Status (37)
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX366703B (es) | 2013-03-15 | 2019-07-22 | Incyte Holdings Corp | Heterociclos tricíclicos como inhibidores de la proteína bet. |
| WO2015006193A1 (en) | 2013-07-08 | 2015-01-15 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
| US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
| WO2015081189A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| US9309246B2 (en) | 2013-12-19 | 2016-04-12 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
| SI3674302T1 (sl) | 2014-04-23 | 2023-07-31 | Incyte Holdings Corporation | 1h-pirolo(2,3-c)piridin-7(6h)-oni in pirazolo(3,4-c)piridin-7(6h)-oni kot zaviralci proteinov bet |
| ES2855225T3 (es) | 2014-09-15 | 2021-09-23 | Incyte Corp | Heterociclos tricíclicos para su uso como inhibidores de proteínas BET |
| MA40940A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| JP6639497B2 (ja) | 2014-11-10 | 2020-02-05 | ジェネンテック， インコーポレイテッド | ブロモドメインインヒビターおよびその使用 |
| MA40943A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| CN107531692B (zh) | 2015-01-29 | 2020-12-25 | 基因泰克公司 | 治疗化合物及其用途 |
| AR104259A1 (es) | 2015-04-15 | 2017-07-05 | Celgene Quanticel Res Inc | Inhibidores de bromodominio |
| US10836742B2 (en) | 2015-08-11 | 2020-11-17 | Neomed Institute | N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals |
| US10501438B2 (en) | 2015-08-11 | 2019-12-10 | Neomed Institute | Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals |
| CN114605387A (zh) | 2015-08-12 | 2022-06-10 | 埃皮吉纳提克斯股份有限公司 | 取代的苯并咪唑、它们的制备和它们作为药物的用途 |
| US10501459B2 (en) | 2015-10-21 | 2019-12-10 | Neomed Institute | Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors |
| US20170121347A1 (en) | 2015-10-29 | 2017-05-04 | Incyte Corporation | Amorphous solid form of a bet protein inhibitor |
| US10519151B2 (en) | 2016-01-28 | 2019-12-31 | Neomed Institute | Substituted [1,2,4]triazolo[4,3-A]pyridines, their preparation and their use as pharmaceuticals |
| SG11201808003RA (en) | 2016-04-15 | 2018-10-30 | Abbvie Inc | Bromodomain inhibitors |
| CR20190027A (es) | 2016-06-20 | 2019-05-16 | Incyte Corp | Formas sólidas cristalinas de un inhibidor de bet |
| WO2018086605A1 (zh) | 2016-11-10 | 2018-05-17 | 山东罗欣药业集团股份有限公司 | 一种含氮大环类化合物、其制备方法、药物组合物及应用 |
| WO2018130174A1 (zh) * | 2017-01-11 | 2018-07-19 | 江苏豪森药业集团有限公司 | 吡咯并[2,3-c]吡啶类衍生物、其制备方法及其在医药上的应用 |
| JP2020527588A (ja) | 2017-07-18 | 2020-09-10 | ニューベイション・バイオ・インコーポレイテッドＮｕｖａｔｉｏｎ Ｂｉｏ Ｉｎｃ． | アデノシンアンタゴニストとしてのヘテロ環式化合物 |
| BR112020000962A2 (pt) | 2017-07-18 | 2020-07-14 | Nuvation Bio Inc. | compostos de 1,8-naftiridinona e usos dos mesmos |
| WO2019086712A1 (en) * | 2017-11-06 | 2019-05-09 | Centre National De La Recherche Scientifique | Xanthine derivatives and uses thereof as inhibitors of bromodomains of bet proteins |
| US11466034B2 (en) * | 2017-12-20 | 2022-10-11 | Betta Pharmaceuticals Co., Ltd. | Compound functioning as bromodomain protein inhibitor, and composition |
| BR112020012197A2 (pt) | 2017-12-21 | 2020-11-24 | Ribon Therapeutics Inc. | quinazolinonas como inibidores de parp14 |
| EP3750885A4 (en) * | 2018-02-06 | 2021-10-27 | Shanghai Haihe Pharmaceutical Co., Ltd. | COMPOUND PRESENTING AN INHIBITORING ACTIVITY OF BET, ITS PREPARATION PROCESS AND ITS USE |
| CN110776508B (zh) | 2018-07-27 | 2021-07-16 | 海创药业股份有限公司 | 一种brd4抑制剂及其制备方法和用途 |
| CN109580433B (zh) * | 2018-10-26 | 2021-05-28 | 中国辐射防护研究院 | 一种常规爆炸放射性气溶胶扩散的源项估算方法 |
| EP3873474A4 (en) | 2018-10-30 | 2022-07-13 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS USED AS BET INHIBITORS |
| CN109432093A (zh) * | 2018-12-23 | 2019-03-08 | 黄泳华 | 由吡唑并吡啶酮类化合物构成的乙酰胆碱酯酶抑制剂的增效体系 |
| CA3126931A1 (en) | 2019-01-18 | 2020-07-23 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
| AU2020208644A1 (en) | 2019-01-18 | 2021-08-26 | Nuvation Bio Inc. | Heterocyclic compounds as adenosine antagonists |
| US12459939B2 (en) | 2019-03-17 | 2025-11-04 | Shanghai Ringene Biopharma Co., Ltd. | Acylaminopyrrolo-pyridone compound, preparation method therefor and use thereof |
| GB201905721D0 (en) | 2019-04-24 | 2019-06-05 | Univ Dundee | Compounds |
| CN110003204B (zh) * | 2019-04-30 | 2020-08-11 | 上海勋和医药科技有限公司 | 一种bet蛋白抑制剂、其制备方法及用途 |
| WO2020253711A1 (zh) * | 2019-06-17 | 2020-12-24 | 中国科学院上海药物研究所 | 一种吡咯并吡啶酮类化合物、其制备方法、其组合物和用途 |
| KR20220024098A (ko) * | 2019-06-19 | 2022-03-03 | 리본 테라퓨틱스 인코포레이티드 | 요법에 사용하기 위한 parp14의 표적화된 단백질 분해 |
| CA3145827A1 (en) | 2019-07-02 | 2021-01-07 | Nuvation Bio Inc. | Heterocyclic compounds as bet inhibitors |
| CN112625036A (zh) * | 2019-10-08 | 2021-04-09 | 上海海和药物研究开发股份有限公司 | 一类具有brd4抑制活性的化合物、其制备方法及用途 |
| US20230119316A1 (en) | 2019-12-27 | 2023-04-20 | Lupin Limited | Substituted Tricyclic Compounds |
| WO2021247064A1 (en) * | 2020-06-03 | 2021-12-09 | Incyte Corporation | Combination of ruxolitinib with incb057643 for treatment of myeloproliferative neoplasms |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| CN115427407B (zh) * | 2020-12-01 | 2024-02-27 | 成都苑东生物制药股份有限公司 | 一种新型n-杂环bet溴结构域抑制剂、其制备方法及医药用途 |
| WO2022132049A1 (en) * | 2020-12-17 | 2022-06-23 | National University Of Singapore | Treating cancers using bet inhibitors |
| GEP20257811B (en) | 2021-01-19 | 2025-10-27 | Lupin Ltd | Pharmaceutical combinations of sos1 inhibitors |
| WO2024138201A2 (en) * | 2022-12-23 | 2024-06-27 | Tay Therapeutics Limited | Selective bet inhibitors and uses thereof |
Family Cites Families (169)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2404E (fr) | 1899-12-05 | 1904-03-26 | Louis Olivier Victor Parmentie | Machine à copier les lettres |
| JPS59170313A (ja) | 1983-03-14 | 1984-09-26 | Kurimoto Iron Works Ltd | スクリ−ンゲ−ト |
| JPS6053449A (ja) | 1983-09-01 | 1985-03-27 | M K Seikou Kk | 洗車機 |
| JPS6085739U (ja) | 1983-11-18 | 1985-06-13 | クラリオン株式会社 | テ−プレコ−ダにおけるピンチロ−ラ装置 |
| JPS6243003U (enExample) | 1985-09-05 | 1987-03-14 | ||
| JPH0314566A (ja) | 1989-06-09 | 1991-01-23 | Sankyo Co Ltd | ベンズイミダゾール誘導体 |
| US5244912A (en) | 1991-03-28 | 1993-09-14 | Eli Lilly And Company | 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz(cd)indoles and pharmaceutical use thereof |
| FR2710915B1 (fr) | 1993-10-04 | 1995-11-24 | Synthelabo | Dérivés de pipéridine, leur préparation et leur utilisation en thérapeutique. |
| GB9410469D0 (en) | 1994-05-25 | 1994-07-13 | Erba Farmitalia | Imidazolylalkyl derivatives of imidazo (5,1-c) (1,4) benzoxazin-1-one and process for their preparation |
| FR2731708B1 (fr) | 1995-03-13 | 1997-04-30 | Synthelabo | Derives de piperidine, leur procede de preparation et leur application en therapeutique |
| FR2747678B1 (fr) | 1996-04-22 | 1998-05-22 | Synthelabo | Composes derives d'imidazobenzoxazine, leurs procedes de preparation et leurs utilisations en therapeutique |
| US6287693B1 (en) | 1998-02-25 | 2001-09-11 | John Claude Savoir | Stable shaped particles of crystalline organic compounds |
| ES2253370T3 (es) | 2000-04-21 | 2006-06-01 | PHARMACIA & UPJOHN COMPANY LLC | Cabergolina para el tratamiento del sindrome de fibromialgia y de fatiga cronica. |
| PL202623B1 (pl) | 2000-06-28 | 2009-07-31 | Smithkline Beecham Plc | Sposób wytwarzania drobno zmielonego preparatu substancji leczniczej, drobno zmielona substancja lecznicza wytworzona tym sposobem i zawierająca ją kompozycja farmaceutyczna |
| EA005950B1 (ru) | 2000-08-08 | 2005-08-25 | Санофи-Авентис | Производные бензимидазола, их получение и терапевтическое применение |
| FR2816619B1 (fr) | 2000-11-15 | 2003-01-31 | Sanofi Synthelabo | Derives de benzimidazole, leur preparation et leur application en therapeutique |
| US6919334B2 (en) | 2002-09-12 | 2005-07-19 | Wyeth | Antidepressant azaheterocyclymethyl derivatives of 4,5-dihydroimidazo[1,4,5-de][1,4]benzoxazine |
| AU2003293006A1 (en) | 2002-11-22 | 2004-06-18 | Japan Tobacco Inc. | Fused bicyclic nitrogen-containing heterocycles |
| EP1462103A1 (en) | 2003-03-25 | 2004-09-29 | Faust Pharmaceuticals | NO donors, combination products and uses as modulators of neurotransmitter release |
| JPWO2005080334A1 (ja) | 2004-02-23 | 2007-08-02 | 大日本住友製薬株式会社 | 新規ヘテロ環化合物 |
| EP1732541A4 (en) | 2004-04-07 | 2008-03-05 | Takeda Pharmaceutical | CYCLIC COMPOUNDS |
| US7713954B2 (en) | 2004-09-30 | 2010-05-11 | Roche Palo Alto Llc | Compositions and methods for treating cognitive disorders |
| DE102005011058A1 (de) | 2005-03-10 | 2006-09-14 | Merck Patent Gmbh | Substituierte Tetrahydro-pyrrolo-chinolinderivate |
| WO2006124874A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
| JP5159305B2 (ja) | 2005-05-30 | 2013-03-06 | 田辺三菱製薬株式会社 | チエノトリアゾロジアゼピン化合物及びその医薬としての用途 |
| CA2616020A1 (en) | 2005-08-05 | 2007-02-15 | Astrazeneca Ab | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators |
| WO2009020677A2 (en) | 2007-04-27 | 2009-02-12 | University Of Rochester | Compositions and methods for inhibiting g protein signaling |
| US9603848B2 (en) | 2007-06-08 | 2017-03-28 | Senomyx, Inc. | Modulation of chemosensory receptors and ligands associated therewith |
| US7928111B2 (en) | 2007-06-08 | 2011-04-19 | Senomyx, Inc. | Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors |
| US8633186B2 (en) | 2007-06-08 | 2014-01-21 | Senomyx Inc. | Modulation of chemosensory receptors and ligands associated therewith |
| WO2009020559A2 (en) | 2007-08-03 | 2009-02-12 | The J. David Gladstone Institutes | Agents that inhibit p-tefb interactions and methods of use thereof |
| KR101600634B1 (ko) | 2007-12-28 | 2016-03-07 | 미쓰비시 타나베 파마 코퍼레이션 | 항암제 |
| DE102008052618A1 (de) | 2008-10-21 | 2010-04-22 | Henkel Ag & Co. Kgaa | Tricyclische Aldehyde und C,H-acide Verbindungen |
| EP2415767B1 (en) | 2009-03-27 | 2014-09-03 | Takeda Pharmaceutical Company Limited | Poly (ADP-ribose) Polymerase (PARP) Inhibitors |
| TW201105681A (en) | 2009-06-10 | 2011-02-16 | Janssen Pharmaceutica Nv | Benzimidazole derivatives useful as TRPM8 channel modulators |
| TW201103941A (en) | 2009-06-10 | 2011-02-01 | Janssen Pharmaceutica Nv | Benzimidazole derivatives useful as TRPM8 channel modulators |
| WO2011024987A1 (ja) | 2009-08-31 | 2011-03-03 | 塩野義製薬株式会社 | 芳香族縮合へテロ環誘導体およびそれらを含有する医薬組成物 |
| GB0919431D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919432D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
| ES2652304T3 (es) | 2009-11-05 | 2018-02-01 | Glaxosmithkline Llc | Compuesto de benzodiacepina novedoso |
| GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| US9102677B2 (en) | 2009-11-05 | 2015-08-11 | Glaxosmithkline Llc | Benzodiazepine bromodomain inhibitor |
| GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| US9360482B2 (en) | 2009-11-05 | 2016-06-07 | Glaxosmithkline Llc | Process for the identification of a compound which inhibits the binding of the second bromodomain of each of human BRD-2, BRD-3, and BRD-4 |
| GB0919426D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| US8927561B2 (en) | 2010-04-23 | 2015-01-06 | Kineta, Inc. | Pyrimidinedione anti-viral compounds |
| EP2902030B1 (en) | 2010-05-14 | 2016-09-14 | Dana-Farber Cancer Institute, Inc. | Thienotriazolodiazepine compounds for treating neoplasia |
| WO2011143660A2 (en) | 2010-05-14 | 2011-11-17 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating leukemia |
| CN103180318B (zh) | 2010-05-14 | 2017-05-10 | 达那-法伯癌症研究所 | 雄性避孕组合物以及使用方法 |
| US20130252331A1 (en) | 2010-05-14 | 2013-09-26 | James Elliott Bradner | Compositions and methods for modulating metabolism |
| JP5844358B2 (ja) | 2010-06-22 | 2016-01-13 | グラクソスミスクライン エルエルシー | ベンゾトリアゾロジアゼピン化合物を含むブロモドメイン阻害剤 |
| US9249161B2 (en) | 2010-12-02 | 2016-02-02 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
| WO2012107465A1 (en) | 2011-02-09 | 2012-08-16 | F. Hoffmann-La Roche Ag | Heterocyclic compounds as pi3 kinase inhibitors |
| AU2012220620A1 (en) | 2011-02-23 | 2013-10-03 | Icahn School Of Medicine At Mount Sinai | Inhibitors of bromodomains as modulators of gene expression |
| RU2013143747A (ru) | 2011-03-21 | 2015-04-27 | Ф. Хоффманн-Ля Рош Аг | Соединения бензоксазепина, селективные в отношении pi3k p110 дельта и способы их применения |
| GB201106750D0 (en) | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
| GB201106799D0 (en) | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
| GB201106743D0 (en) | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
| GB201107325D0 (en) | 2011-05-04 | 2011-06-15 | Glaxosmithkline Llc | Novel compounds |
| WO2012151512A2 (en) | 2011-05-04 | 2012-11-08 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| US9145391B2 (en) | 2011-05-10 | 2015-09-29 | Merck Sharp & Dohme Corp. | Bipyridylaminopyridines as Syk inhibitors |
| WO2012174487A2 (en) | 2011-06-17 | 2012-12-20 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| WO2012178208A2 (en) | 2011-06-24 | 2012-12-27 | The Trustees Of The Stevens Institute Of Technology | Selective inhibitors of histone deacetylase isoform 6 and methods thereof |
| JP2013010719A (ja) | 2011-06-30 | 2013-01-17 | Dainippon Sumitomo Pharma Co Ltd | ベンズイミダゾロンおよびオキシインドール誘導体ならびにそれらの医薬用途 |
| WO2013019710A1 (en) | 2011-07-29 | 2013-02-07 | The Children's Hospital Of Philadelphia | Compositions and methods for the treatment of hiv |
| GB201114103D0 (en) | 2011-08-17 | 2011-09-28 | Glaxosmithkline Llc | Novel compounds |
| WO2013027168A1 (en) | 2011-08-22 | 2013-02-28 | Pfizer Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
| WO2013033269A1 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same |
| WO2013033268A2 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bivalent bromodomain ligands, and methods of using same |
| JP6106174B2 (ja) | 2011-08-31 | 2017-03-29 | 大塚製薬株式会社 | キノロン化合物 |
| DE102011082013A1 (de) | 2011-09-01 | 2013-03-07 | Bayer Pharma AG | 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine |
| ES2632443T3 (es) | 2011-09-22 | 2017-09-13 | Viiv Healthcare Uk Limited | Compuestos de pirrolopiridinona y procedimientos de tratamiento del VIH |
| CN103857391B (zh) | 2011-09-30 | 2016-06-08 | 沈阳蓝桑医药生物技术研发有限公司 | 含有瑞利格内酯的药物组合物及其应用 |
| EP2771340B1 (en) | 2011-10-25 | 2016-04-13 | Sanofi | 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| LT2773354T (lt) | 2011-11-01 | 2019-08-12 | Resverlogix Corp. | Geriamosios greitai atsipalaiduojančios pakeistų chinozolinų vaisto formos |
| WO2013097052A1 (en) * | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| US20150133434A1 (en) | 2012-03-28 | 2015-05-14 | The J. David Gladstone Institutes | Compositions and Methods for Reactivating Latent Immunodeficiency Virus |
| US20130281398A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| US20130281397A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| US20130281399A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| US20130281396A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| CA2870931A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Isoindolone derivatives |
| WO2013184878A1 (en) | 2012-06-06 | 2013-12-12 | Constellation Pharmaceuticals, Inc. | Benzo [b] isoxazoloazepine bromodomain inhibitors and uses thereof |
| TWI602820B (zh) | 2012-06-06 | 2017-10-21 | 星宿藥物公司 | 溴域抑制劑及其用途 |
| EP2858982A4 (en) | 2012-06-12 | 2015-11-11 | Abbvie Inc | PYRIDINONE AND PYRIDAZINONE DERIVATIVES |
| MX2014015986A (es) | 2012-06-25 | 2016-02-11 | Oncoethix Gmbh | Metodo para tratar linfoma utilizando compuestos de tienotriazolodiazepina. |
| WO2014015175A1 (en) | 2012-07-18 | 2014-01-23 | Massachusetts Institute Of Technology | Compositions and methods for modulating brd4 bioactivity |
| US20150238507A1 (en) | 2012-08-16 | 2015-08-27 | Glaxosmithkline Llc | Benzodiazepines for treating small cell lung cancer |
| KR20150041787A (ko) | 2012-08-16 | 2015-04-17 | 바이엘 파마 악티엔게젤샤프트 | 2,3-벤조디아제핀 |
| EP2900221B1 (en) | 2012-09-28 | 2019-03-06 | Oncoethix GmbH | Pharmaceutical formulation containing thienotriazolodiazepine compounds |
| US9663523B2 (en) | 2012-09-28 | 2017-05-30 | Bayer Pharma Aktiengesellschaft | BET protein-inhibiting 5-aryltriazoleazepines |
| EP2917181B1 (en) | 2012-11-09 | 2019-09-25 | Jacobus Pharmaceutical Company, Inc. | Heteroaryl derivatives and uses thereof |
| US9422290B2 (en) | 2012-11-13 | 2016-08-23 | Boehringer Ingelheim International Gmbh | Triazolopyridazine |
| ES2625945T3 (es) | 2012-11-14 | 2017-07-21 | Glaxosmithkline Llc | Tieno[3,2-c]piridin-4(5H)-onas como inhibidores de bet |
| US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
| WO2014080291A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Biaryl derivatives as bromodomain inhibitors |
| HK1213899A1 (zh) | 2012-12-20 | 2016-07-15 | Bayer Pharma Aktiengesellschaft | 抑制bet蛋白的二氢吡啶并吡嗪酮 |
| EP2935261A1 (de) | 2012-12-20 | 2015-10-28 | Bayer Pharma Aktiengesellschaft | Bet-proteininhibitorische dihydrochinoxalinone |
| MX2015007921A (es) | 2012-12-21 | 2016-03-03 | Zenith Epigenetics Corp | Compuestos heterociclicos novedosos como inhibidores de bromodominio. |
| WO2014128655A1 (en) | 2013-02-25 | 2014-08-28 | Aurigene Discovery Technologies Limited | Substituted imidazo[4,5-c]quinoline derivatives as bromodomain inhibitors |
| US9492460B2 (en) | 2013-02-27 | 2016-11-15 | Bristol-Myers Squibb Company | Carbazole compounds useful as bromodomain inhibitors |
| EP2961747B1 (en) | 2013-02-27 | 2017-11-15 | Bristol-Myers Squibb Company | Carbazole compounds useful as bromodomain inhibitors |
| EP2970285B1 (en) | 2013-03-11 | 2019-04-17 | AbbVie Inc. | Fused tetracyclic bromodomain inhibitors |
| CN105377851B (zh) | 2013-03-11 | 2018-07-20 | 密执安州立大学董事会 | Bet布罗莫结构域抑制剂和使用这些抑制剂的治疗方法 |
| JP2016512524A (ja) | 2013-03-11 | 2016-04-28 | アッヴィ・インコーポレイテッド | ブロモドメイン阻害剤 |
| CN105164113B (zh) | 2013-03-12 | 2018-03-02 | 艾伯维公司 | 吡咯酰胺抑制剂 |
| CN105026403B (zh) | 2013-03-12 | 2018-05-18 | 艾伯维公司 | 四环布罗莫结构域抑制剂 |
| HK1218909A1 (zh) | 2013-03-12 | 2017-03-17 | Abbvie Inc. | 二氢-吡咯并吡啶酮布罗莫结构域抑制剂 |
| WO2014159392A1 (en) | 2013-03-14 | 2014-10-02 | Dana-Farber Cancer Institute, Inc. | Bromodomain binding reagents and uses thereof |
| EP2968360B1 (en) | 2013-03-14 | 2021-01-20 | ConverGene LLC | Quinolinone derivatives for the inhibition of bromodomain-containing proteins |
| WO2014140077A1 (en) | 2013-03-14 | 2014-09-18 | Glaxosmithkline Intellectual Property (No.2) Limited | Furopyridines as bromodomain inhibitors |
| ES2704048T3 (es) | 2013-03-14 | 2019-03-14 | Glaxosmithkline Ip No 2 Ltd | Derivados de 1-acil-4-amino-1,2,3,4-tetrahidroquinolina-2,3-disustituida y su uso como inhibidores de bromodominio |
| US20160039842A1 (en) | 2013-03-15 | 2016-02-11 | Epigenetix, Inc. | Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors |
| MX366703B (es) | 2013-03-15 | 2019-07-22 | Incyte Holdings Corp | Heterociclos tricíclicos como inhibidores de la proteína bet. |
| NZ630875A (en) | 2013-03-15 | 2017-12-22 | Plexxikon Inc | Heterocyclic compounds and uses thereof |
| US9102684B2 (en) | 2013-03-27 | 2015-08-11 | Boehringer Ingelheim International Gmbh | Indolinone analogues |
| EP2978758B1 (en) | 2013-03-27 | 2017-02-08 | Boehringer Ingelheim International GmbH | Dihydroquinazolinone analogues as brd4 inhibitors |
| TWI530499B (zh) | 2013-03-28 | 2016-04-21 | 吉李德科學股份有限公司 | 作為溴結構域（ｂｒｏｍｏｄｏｍａｉｎ）抑制劑之苯並咪唑酮衍生物類 |
| WO2014170350A1 (en) | 2013-04-17 | 2014-10-23 | Albert Ludwigs Universität Freiburg | Compounds for use as bromodomain inhibitors |
| CA2901083A1 (en) | 2013-04-26 | 2014-10-30 | Beigene, Ltd. | Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones |
| TWI527811B (zh) | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
| EP3004109A1 (en) | 2013-05-27 | 2016-04-13 | Novartis AG | Imidazopyrrolidinone derivatives and their use in the treatment of disease |
| US8975417B2 (en) | 2013-05-27 | 2015-03-10 | Novartis Ag | Pyrazolopyrrolidine derivatives and their use in the treatment of disease |
| MX2015016421A (es) | 2013-05-28 | 2016-03-03 | Novartis Ag | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. |
| EA028035B1 (ru) | 2013-05-28 | 2017-09-29 | Новартис Аг | Производные пиразолопирролидин-4-она и их применение при лечении заболевания |
| ITMI20130991A1 (it) | 2013-06-17 | 2014-12-18 | Industrie De Nora Spa | Sistema per la misurazione di correnti presenti sugli elettrodi in celle elettrolitiche interconnesse. |
| CA2915419A1 (en) | 2013-06-17 | 2014-12-24 | Bayer Pharma Aktiengesellschaft | Substituted phenyl-2,3-benzodiazepines |
| WO2015004534A2 (en) | 2013-06-21 | 2015-01-15 | Zenith Epigenetics Corp. | Novel substituted bicyclic compounds as bromodomain inhibitors |
| CN105407888B (zh) | 2013-06-21 | 2019-05-21 | 齐尼思表观遗传学有限公司 | 新双环溴结构域抑制剂 |
| MX2015017963A (es) | 2013-06-28 | 2016-11-10 | Abbvie Inc | Inhibidores de bromodominio. |
| AR096758A1 (es) | 2013-06-28 | 2016-02-03 | Abbvie Inc | Inhibidores cristalinos de bromodominios |
| WO2015006193A1 (en) | 2013-07-08 | 2015-01-15 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
| JP6441334B2 (ja) | 2013-07-16 | 2018-12-19 | ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ | 除草性アジン |
| CA2918910A1 (en) | 2013-07-25 | 2015-01-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of transcription factors and uses thereof |
| KR101672096B1 (ko) | 2013-09-30 | 2016-11-02 | 주식회사 엘지화학 | 헤테로환 화합물 및 이를 포함하는 유기 발광 소자 |
| EA035727B1 (ru) | 2013-10-18 | 2020-07-31 | Селджен Квонтисел Рисёрч, Инк. | Ингибиторы бромодомена |
| WO2015081246A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| WO2015081189A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
| CN105939996A (zh) | 2013-12-09 | 2016-09-14 | 艾伯维公司 | 用作布罗莫结构域抑制剂的二氢吡啶酮和二氢哒嗪酮衍生物 |
| US9309246B2 (en) | 2013-12-19 | 2016-04-12 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
| WO2015095445A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
| LT3092227T (lt) | 2014-01-09 | 2018-08-10 | Orion Corporation | Bicikliniai heterocikliniai dariniai kaip bromodomeno inhibitoriai |
| WO2015131005A1 (en) | 2014-02-28 | 2015-09-03 | The Regents Of The University Of Michigan | 9h-pyrimido[4,5-b]indoles and related analogs as bet bromodomain inhibitors |
| BR112016022782B1 (pt) | 2014-04-23 | 2020-01-28 | Basf Se | composto de diaminotriazina, composição agroquímica e uso de um composto |
| EA030373B1 (ru) | 2014-04-23 | 2018-07-31 | Такеда Фармасьютикал Компани Лимитед | Изоиндолин-1-оновые производные в качестве положительных аллостерических модуляторов холинергического мускаринового m1 рецептора для лечения болезни альцгеймера |
| SI3674302T1 (sl) | 2014-04-23 | 2023-07-31 | Incyte Holdings Corporation | 1h-pirolo(2,3-c)piridin-7(6h)-oni in pirazolo(3,4-c)piridin-7(6h)-oni kot zaviralci proteinov bet |
| RU2016146099A (ru) | 2014-05-02 | 2018-06-05 | Онкоэтикс Гмбх | Способ лечения острого миелоидного лейкоза и/или острого лимфобластного лейкоза с помощью тиенотриазолодиазепиновых соединений |
| JP2017514907A (ja) | 2014-05-02 | 2017-06-08 | オンコエシックス ゲーエムベーハー | チエノトリアゾロジアゼピン化合物を用いる耐性非ホジキンリンパ腫、髄芽腫及び／又はａｌｋ＋非小細胞肺癌の治療方法 |
| WO2015169953A1 (en) | 2014-05-08 | 2015-11-12 | Oncoethix Gmbh | Method of treating glioma using thienotriazolodiazepine compounds |
| MX2016014574A (es) | 2014-05-08 | 2017-02-23 | Oncoethix Gmbh | El uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de mama triple-negativo. |
| EP3148543B1 (en) | 2014-05-30 | 2020-04-08 | Icahn School of Medicine at Mount Sinai | Small molecule transcription modulators of bromodomains |
| PT3157928T (pt) | 2014-06-20 | 2019-05-30 | Constellation Pharmaceuticals Inc | Formas cristalinas de 2-((4s)-6-(4-clorofenil)-1-metil-4h-benzo[c] isoxazolo[4,5-e]azepin-4-il)acetamida |
| ES2855225T3 (es) | 2014-09-15 | 2021-09-23 | Incyte Corp | Heterociclos tricíclicos para su uso como inhibidores de proteínas BET |
| PE20190710A1 (es) | 2014-10-24 | 2019-05-17 | Bristol Myers Squibb Co | Compuestos de indol carboxamida utiles como inhibidores de cinasas |
| MA40943A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| EP3253756B1 (en) | 2015-02-03 | 2021-09-22 | Trillium Therapeutics Inc. | Fluorinated imidazo[4,5-c]quinoline derivatives as inhibitors of bromodomain containing proteins |
| WO2016186453A1 (en) | 2015-05-20 | 2016-11-24 | Kainos Medicine, Inc. | Quinoline derivatives as bromodomain inhibitors |
| CA2987384A1 (en) | 2015-05-29 | 2016-12-08 | Shionogi & Co., Ltd. | Nitrogen-containing tricyclic derivative having hiv replication inhibitory activity |
| CN105039258B (zh) | 2015-07-03 | 2018-04-17 | 北京大学 | 将非神经元细胞重编程为神经元样细胞的方法和组合物 |
| US20170121347A1 (en) | 2015-10-29 | 2017-05-04 | Incyte Corporation | Amorphous solid form of a bet protein inhibitor |
| CN105254635A (zh) | 2015-10-30 | 2016-01-20 | 中国药科大学 | 一类咪唑并吡嗪类化合物及其药物组合物和用途 |
| US20170127985A1 (en) | 2015-11-11 | 2017-05-11 | Medtronic Minimed, Inc. | Sensor set |
| CA3007168A1 (en) | 2015-12-14 | 2017-06-22 | Zenith Epigenetics Ltd. | 1h-imidazo[4,5-b]pyridinyl and 2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridinyl heterocyclic bet bromodomain inhibitors |
| US10519151B2 (en) | 2016-01-28 | 2019-12-31 | Neomed Institute | Substituted [1,2,4]triazolo[4,3-A]pyridines, their preparation and their use as pharmaceuticals |
| US20190040063A1 (en) | 2016-02-05 | 2019-02-07 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Tricyclic compound for bromodomain-containing protein inhibitor and preparation pharmaceutical composition, and application thereof |
| CR20190027A (es) | 2016-06-20 | 2019-05-16 | Incyte Corp | Formas sólidas cristalinas de un inhibidor de bet |
| CN108069958A (zh) | 2016-11-10 | 2018-05-25 | 凯惠科技发展(上海)有限公司 | 一种含氮杂环类化合物、其制备方法、药物组合物及应用 |
-
2015
- 2015-04-22 SI SI201531941T patent/SI3674302T1/sl unknown
- 2015-04-22 PE PE2016002116A patent/PE20170144A1/es active IP Right Grant
- 2015-04-22 AR ARP150101214A patent/AR100160A1/es active IP Right Grant
- 2015-04-22 CN CN201580025765.3A patent/CN106414442B/zh active Active
- 2015-04-22 EP EP23157487.2A patent/EP4218766A1/en active Pending
- 2015-04-22 HU HUE20156599A patent/HUE061770T2/hu unknown
- 2015-04-22 TW TW104112916A patent/TWI672301B/zh active
- 2015-04-22 CR CR20160542A patent/CR20160542A/es unknown
- 2015-04-22 DK DK15721085.7T patent/DK3134403T3/da active
- 2015-04-22 PL PL20156599.1T patent/PL3674302T3/pl unknown
- 2015-04-22 MY MYPI2020005045A patent/MY198727A/en unknown
- 2015-04-22 NZ NZ725930A patent/NZ725930A/en unknown
- 2015-04-22 EA EA202090371A patent/EA039678B1/ru unknown
- 2015-04-22 EP EP15721085.7A patent/EP3134403B1/en active Active
- 2015-04-22 NZ NZ763740A patent/NZ763740A/en unknown
- 2015-04-22 ES ES15721085T patent/ES2784846T3/es active Active
- 2015-04-22 US US14/693,424 patent/US9540368B2/en active Active
- 2015-04-22 HR HRP20200564TT patent/HRP20200564T1/hr unknown
- 2015-04-22 SM SM20230154T patent/SMT202300154T1/it unknown
- 2015-04-22 KR KR1020227026808A patent/KR102702503B1/ko active Active
- 2015-04-22 KR KR1020247029041A patent/KR20240134245A/ko active Pending
- 2015-04-22 MY MYPI2023001544A patent/MY207899A/en unknown
- 2015-04-22 WO PCT/US2015/027047 patent/WO2015164480A1/en not_active Ceased
- 2015-04-22 AU AU2015249810A patent/AU2015249810B2/en active Active
- 2015-04-22 RS RS20230379A patent/RS64231B1/sr unknown
- 2015-04-22 CR CR20200231A patent/CR20200231A/es unknown
- 2015-04-22 LT LTEP20156599.1T patent/LT3674302T/lt unknown
- 2015-04-22 TW TW108123445A patent/TWI735002B/zh active
- 2015-04-22 JP JP2016563976A patent/JP6572237B2/ja active Active
- 2015-04-22 HR HRP20230340TT patent/HRP20230340T1/hr unknown
- 2015-04-22 MY MYPI2016001898A patent/MY180775A/en unknown
- 2015-04-22 KR KR1020167032545A patent/KR102430144B1/ko active Active
- 2015-04-22 ES ES20156599T patent/ES2942723T3/es active Active
- 2015-04-22 DK DK20156599.1T patent/DK3674302T3/da active
- 2015-04-22 HU HUE15721085A patent/HUE049627T2/hu unknown
- 2015-04-22 MA MA39985A patent/MA39985B1/fr unknown
- 2015-04-22 LT LTEP15721085.7T patent/LT3134403T/lt unknown
- 2015-04-22 SG SG10201809353TA patent/SG10201809353TA/en unknown
- 2015-04-22 BR BR112016024626-8A patent/BR112016024626B1/pt active IP Right Grant
- 2015-04-22 PT PT201565991T patent/PT3674302T/pt unknown
- 2015-04-22 PT PT157210857T patent/PT3134403T/pt unknown
- 2015-04-22 UA UAA201611803A patent/UA119870C2/uk unknown
- 2015-04-22 FI FIEP20156599.1T patent/FI3674302T3/fi active
- 2015-04-22 SG SG11201608843TA patent/SG11201608843TA/en unknown
- 2015-04-22 EP EP20156599.1A patent/EP3674302B1/en active Active
- 2015-04-22 ME MEP-2020-64A patent/ME03763B/me unknown
- 2015-04-22 NZ NZ763737A patent/NZ763737A/en unknown
- 2015-04-22 RS RS20200395A patent/RS60139B1/sr unknown
- 2015-04-22 MX MX2016013851A patent/MX376174B/es active IP Right Grant
- 2015-04-22 CA CA2946731A patent/CA2946731C/en active Active
- 2015-04-22 EA EA201692134A patent/EA034972B1/ru unknown
- 2015-04-22 SM SM20200133T patent/SMT202000133T1/it unknown
- 2015-04-22 SI SI201531116T patent/SI3134403T1/sl unknown
- 2015-04-22 PL PL15721085T patent/PL3134403T3/pl unknown
-
2016
- 2016-10-20 IL IL248415A patent/IL248415B/en active IP Right Grant
- 2016-10-21 MX MX2020011035A patent/MX2020011035A/es unknown
- 2016-10-21 PH PH12016502115A patent/PH12016502115B1/en unknown
- 2016-10-21 CL CL2016002681A patent/CL2016002681A1/es unknown
- 2016-11-17 US US15/354,223 patent/US9957268B2/en active Active
- 2016-11-18 EC ECIEPI201688983A patent/ECSP16088983A/es unknown
-
2018
- 2018-03-21 US US15/927,170 patent/US10472358B2/en active Active
-
2019
- 2019-07-15 AU AU2019205984A patent/AU2019205984B2/en active Active
- 2019-08-09 JP JP2019147776A patent/JP6745390B2/ja active Active
- 2019-10-21 US US16/658,445 patent/US10781209B2/en active Active
-
2020
- 2020-03-04 IL IL273049A patent/IL273049B/en active IP Right Grant
- 2020-04-27 CY CY20201100382T patent/CY1122948T1/el unknown
- 2020-08-14 US US16/994,172 patent/US11059821B2/en active Active
-
2021
- 2021-01-22 AU AU2021200450A patent/AU2021200450B2/en active Active
- 2021-03-04 IL IL281263A patent/IL281263B/en unknown
- 2021-06-04 US US17/339,546 patent/US11702416B2/en active Active
-
2023
- 2023-05-18 CY CY20231100237T patent/CY1126052T1/el unknown
- 2023-05-31 US US18/204,136 patent/US12227502B2/en active Active
-
2025
- 2025-01-10 US US19/016,425 patent/US20250145621A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017513879A5 (enExample) | ||
| HRP20200564T1 (hr) | 1h-pirolo[2,3-c]piridin-7(6h)-oni i pirazolo[3,4-c]piridin-7(6h)-oni kao inhibitori bet proteina | |
| ES2608940T3 (es) | Derivado de bicicloanilina | |
| AU2017353986B2 (en) | Substituted pyridinone-containing tricyclic compounds, and methods using same | |
| US10975080B2 (en) | Compounds and compositions for inhibiting the activity of SHP2 | |
| KR102819704B1 (ko) | 항바이러스제로서의 작용화된 헤테로사이클 | |
| AU2013213474B2 (en) | New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same | |
| AU2015280138B2 (en) | Phosphatidylinositol 3-kinase inhibitors | |
| AU2017286380B2 (en) | Azabenzimidazole derivatives as PI3K beta inhibitors | |
| KR101961500B1 (ko) | 세린/트레오닌 키나제 억제제 | |
| WO2020253862A1 (zh) | 含氮芳基磷氧化物类衍生物、其制备方法和应用 | |
| AU2022210517A1 (en) | Pharmaceutical combinations of sos1 inhibitors for treating and/or preventing cancer | |
| AU2015274626C1 (en) | Quinazolinone derivatives as phosphatidylinositol 3-kinase inhibitors | |
| EP3759112A1 (en) | Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors | |
| CN112079830A (zh) | 含并环类衍生物抑制剂、其制备方法和应用 | |
| CN106132956A (zh) | 一类杂环化合物、其制备方法和用途 | |
| ES2946632T3 (es) | Moduladores de AHR | |
| TW202015677A (zh) | 用於治療疾病之新穎化合物及其醫藥組合物 | |
| RU2014130125A (ru) | Новые пиррольные соединения, способ их получения и фармацевтические композиции, содержащие их | |
| ES2580530T3 (es) | Compuesto con anillo fusionado de quinolilpirrolopirimidilo o sal del mismo | |
| CA3211110A1 (en) | 4-aminoquinazoline compound | |
| JP2022500466A (ja) | 抗ウイルス剤としての官能化複素環 | |
| CN117736226A (zh) | 泛-kras抑制剂及其在医药上的应用 | |
| CN119585261A (zh) | 一种prmt5抑制剂、其制备方法及应用 | |
| KR20230012547A (ko) | 의학적 장애의 치료를 위한 시클린-의존성 키나제 억제 화합물 |